clarithromycin + ofloxacin + rifaximin

This drug entry refers to a specific antibiotic combination regimen consisting of clarithromycin, ofloxacin, and rifaximin, being evaluated by the All India Institute of Medical Sciences, Bhubaneswar, for the treatment of granulomatous lobular mastitis (GLM). GLM is a rare, chronic inflammatory breast condition that typically affects young women post-childbirth. The regimen is being studied in a Phase 1/2 clinical trial as an alternative to standard corticosteroid therapy. Clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis, ofloxacin is a fluoroquinolone that targets bacterial DNA replication enzymes, and rifaximin is a non-absorbable rifamycin derivative that inhibits bacterial RNA synthesis. The trial aims to determine if this antibiotic approach can provide faster clinical response and lower recurrence rates compared to tapering doses of prednisolone.

Other names

clarithromycin + ofloxacin + rifaximin regimenclarithromycin and ofloxacin combination therapy